Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.

As showed in Figure 6 C, the TMERSscore of patients in early stage (Stage I and Stage II) was significantly lower than that of patients in advanced stage (Stage III and Stage IV), and there was an increasing trend of TMERSscore with tumor progression, which could also be observed in different stages of T, N, and M ( Figure 6 E–G).

also in 63,971 other papers